A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes
Summary
This study will be conducted in participants with type 1 diabetes mellitus on continuous subcutaneous insulin infusion (CSII) or pump therapy to evaluate the effect of LY900014 (Lyumjev) on blood sugar levels during exercise using different approaches on basal rate reduction and following a test meal compared to insulin lispro (Humalog). The study may last up to approximately 10 weeks and may include up to 7 visits.
Timeline
- Start
- 2022-02-14
- Primary completion
- 2023-03-07
- Completion
- 2023-03-07
Outcome
Met primary endpoint
registry Lyumjev With 50% Basal Rate Reduction vs Humalog With 50% Basal Rate Reduction; p = 0.0494; Mean Difference (Final Values) 9.32 NCT05262387 ↗
registry Lyumjev With 100% Basal Rate Reduction vs Humalog With 100% Basal Rate Reduction; p = 0.0028; Mean Difference (Final Values) 14.1 NCT05262387 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Insulin Lispro | Protein / enzyme biologic | — | Subcutaneous |
| Subject | Lyumjev | Unknown | — | Subcutaneous |